ReviewImmunological reviews2017
LAG3 (CD223) as a cancer immunotherapy target.
Lawrence P Andrews et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
618 papers cite itlatest 60 shown
this paperpooled ittrialcites it
ReviewImmunological reviews2017
Lawrence P Andrews et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.